

Rydym yn croesawu gohebiaeth yn y Gymraeg neu'r Saesneg. Atebir gohebiaeth Gymraeg yn y Gymraeg, ac ni fydd hyn yn arwain at oedi. We welcome correspondence in Welsh or English. Welsh language correspondence will be replied to in Welsh, and this will not lead to a delay.

Cais Rhyddid Gwybodaeth / Freedom of Information request **Ein Cyf / Our Ref: 22-G-023**

Please note that we have provided this information for the period April to June 2022.

You asked:

1. How many patients were treated in the past 3 months for gastric and gastro-oesophageal junction cancer (any stage) with:

| | |
|---|-----|
| CAPOX (Capecitabine with Oxaliplatin) | 0 |
| FOLFOX (Folinic acid, Fluorouracil and Oxaliplatin) | 0 |
| Pembrolizumab in combination with Platinum (Cisplatin or Oxaliplatin) and Fluoropyrimidine (5-Fluorouracil or Capecitabine) | <5* |
| Any other systemic anti-cancer therapy | <5* |
| Palliative care only | ** |

2. How many patients were treated in the past 3 months for Oesophageal cancer (any stage) with:

| | |
|---|-----|
| Pembrolizumab in combination with Platinum (Cisplatin or Oxaliplatin) and Fluoropyrimidine (5-Fluorouracil or Capecitabine) | <5* |
| Platinum and Fluoropyrimidine based combination treatments (Cisplatin or Oxaliplatin with 5-Fluorouracil or Capecitabine) | <5* |
| Nivolumab monotherapy | 5 |
| Nivolumab and Ipilimumab | 0 |
| Any other systemic anti-cancer therapy | 14 |
| Palliative care only | ** |

3. Of the Oesophageal Cancer patients (from Q2) treated with Pembrolizumab in the past 3 months, how many patients were treated for:

- **Oesophageal adenocarcinoma** - <5* patients
- **Oesophageal squamous cell carcinoma** - <5* patients



4. How many patients were treated in the past 3 months for advanced/metastatic oesophageal cancer ONLY with:

- **Pembrolizumab in combination with Platinum (Cisplatin or Oxaliplatin) and Fluoropyrimidine (5-Fluorouracil or Capecitabine)**
- **Platinum and Fluoropyrimidine based combination treatments (Cisplatin or Oxaliplatin with 5-Fluorouracil or Capecitabine)**
- **Nivolumab monotherapy**
- **Nivolumab and Ipilimumab**
- **Any other systemic anti-cancer therapy**
- **Palliative care only**

| | |
|---|-----|
| Pembrolizumab in combination with Platinum (Cisplatin or Oxaliplatin) and Fluoropyrimidine (5-Fluorouracil or Capecitabine) | <5* |
| Platinum and Fluoropyrimidine based combination treatments (Cisplatin or Oxaliplatin with 5-Fluorouracil or Capecitabine) | <5* |
| Nivolumab monotherapy | <5* |
| Nivolumab and Ipilimumab | 0 |
| Any other systemic anti-cancer therapy | 5 |
| Palliative care only | ** |

* Where fewer than 5 has been indicated we are unable to provide you with the exact number of patients as due to the low numbers, there is a potential risk of identifying individuals if this was disclosed. We are therefore withholding this detail under Section 40(2) of the Freedom of Information Act 2000. This information is protected by the General Data Protection Regulation (GDPR) and Data Protection Act 2018 and its disclosure would be contrary to the data protection principles and constitute as unfair and unlawful processing in regard to Articles 5, 6, and 9 of GDPR. This exemption is absolute and therefore there is no requirement to apply the public interest test.

** To obtain this information would involve a manual trawl and search of records which we have estimated would significantly exceed the 18 hours limit set down by the FOI Act as the reasonable limit. Section 12 of the FOI Act and The Freedom of Information and Data Protection (Appropriate Limit and Fees) Regulation 2004 provides that we are not obliged to spend in excess of 18 hours in any sixty day period locating, retrieving and identifying information in order to deal with a request for information and therefore we are withholding this information at this time.

